DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Cyclophosphamide (Cyclophosphamide) - Nausea - Suspected Cause - Side Effect Reports

 
 



Index of reports > Cases with Nausea (171)

Below is the selection of side effect reports (a.k.a. adverse event reports) related to Cyclophosphamide where reactions include nausea. The selected reports were submitted to the FDA during the sample period of about a year.

 Reports 1 - 30 of 171   Next >>

Possible Cyclophosphamide side effects in female

Reported by a physician from Sweden on 2012-08-20

Patient: female

Reactions: Nausea, Progressive Multifocal Leukoencephalopathy, Hepatic Enzyme Increased

Adverse event resulted in: death

Drug(s) suspected as cause:
Azathioprine
    Dosage: 150 mg/day
    Administration route: Oral
    Indication: Polymyositis

Cyclophosphamide
    Dosage: 100 mg/day
    Administration route: Oral
    Indication: Polymyositis

Methotrexate
    Dosage: 20 mg/week
    Indication: Polymyositis

Methylprednisolone

Prednisone
    Dosage: 10mg daily

Prednisone
    Dosage: 17.5 mg/day
    Administration route: Oral

Prednisone
    Dosage: 60 mg/day

Prednisone
    Dosage: 2.5 mg/day

Prednisone
    Dosage: 40 mg/day
    Indication: Polymyositis



Possible Cyclophosphamide side effects in female

Reported by a physician from Sweden on 2012-08-20

Patient: female

Reactions: Nausea, Progressive Multifocal Leukoencephalopathy, Hepatic Enzyme Increased

Adverse event resulted in: death

Drug(s) suspected as cause:
Azathioprine
    Dosage: 150 mg/day
    Administration route: Oral
    Indication: Polymyositis

Cyclophosphamide
    Dosage: 100 mg/day
    Administration route: Oral
    Indication: Polymyositis

Methotrexate
    Dosage: 20 mg/week
    Indication: Polymyositis

Methylprednisolone

Prednisone
    Dosage: 40 mg/day
    Indication: Polymyositis

Prednisone
    Dosage: 10mg daily

Prednisone
    Dosage: 17.5 mg/day
    Administration route: Oral

Prednisone
    Dosage: 60 mg/day

Prednisone
    Dosage: 2.5 mg/day



Possible Cyclophosphamide side effects in female

Reported by a physician from Sweden on 2012-08-20

Patient: female

Reactions: Nausea, Progressive Multifocal Leukoencephalopathy, Hepatic Enzyme Increased

Adverse event resulted in: death

Drug(s) suspected as cause:
Azathioprine
    Dosage: 150 mg/day
    Administration route: Oral
    Indication: Polymyositis

Cyclophosphamide
    Dosage: 100 mg/day
    Administration route: Oral
    Indication: Polymyositis

Methotrexate
    Dosage: 20 mg/week
    Indication: Polymyositis

Methylprednisolone

Prednisone
    Dosage: 40 mg/day
    Indication: Polymyositis

Prednisone
    Dosage: 2.5 mg/day

Prednisone
    Dosage: 10mg daily

Prednisone
    Dosage: 60 mg/day

Prednisone
    Dosage: 17.5 mg/day
    Administration route: Oral



Possible Cyclophosphamide side effects in

Reported by a health professional (non-physician/pharmacist) from Italy on 2012-08-20

Patient:

Reactions: Abdominal Pain, Vomiting, Hypersensitivity, Nausea, Skin Toxicity, Mucosal Inflammation, Fatigue, Diarrhoea, Hepatotoxicity, Neutropenia

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Cyclophosphamide
    Indication: Breast Cancer

Epirubicin
    Indication: Breast Cancer

Fluorouracil
    Indication: Breast Cancer

Herceptin
    Dosage: loading dose
    Indication: Breast Cancer

Herceptin
    Dosage: maintenance dose

Lapatinib
    Dosage: arm b
    Administration route: Oral
    Indication: Breast Cancer

Lapatinib
    Dosage: arm c
    Administration route: Oral

Paclitaxel
    Indication: Breast Cancer



Possible Cyclophosphamide side effects in

Reported by a physician from United States on 2012-08-16

Patient:

Reactions: Nausea, Pain, Motor Dysfunction, Rash, Peripheral Sensory Neuropathy, Fatigue, Blood Potassium Decreased, Dyspepsia, Diarrhoea, Neutropenia, Thrombocytopenia

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: on day 1

Cyclophosphamide
    Dosage: on day 1
    Indication: Lymphocytic Lymphoma

Cyclophosphamide
    Dosage: on day 1
    Indication: non-Hodgkin's Lymphoma

Cyclophosphamide
    Dosage: on day 1
    Indication: B-Cell Lymphoma

Cyclophosphamide
    Dosage: on day 1
    Indication: Lymphoma

Cyclophosphamide
    Dosage: on day 1
    Indication: Waldenstrom's Macroglobulinaemia

Doxorubicin HCL
    Dosage: on day 1
    Indication: non-Hodgkin's Lymphoma

Doxorubicin HCL
    Dosage: on day 1

Doxorubicin HCL
    Dosage: on day 1

Doxorubicin HCL
    Dosage: on day 1
    Indication: Lymphoma

Doxorubicin HCL
    Dosage: on day 1

Doxorubicin HCL
    Dosage: on day 1
    Indication: Waldenstrom's Macroglobulinaemia

Doxorubicin HCL
    Dosage: on day 1
    Indication: B-Cell Lymphoma

Doxorubicin HCL
    Dosage: on day 1

Doxorubicin HCL
    Dosage: on day 1
    Indication: Lymphocytic Lymphoma

Doxorubicin HCL
    Dosage: on day 1

Doxorubicin HCL
    Dosage: on day 1

Doxorubicin HCL
    Dosage: on day 1

Prednisone TAB
    Dosage: on days 1-5
    Administration route: Oral
    Indication: B-Cell Lymphoma

Prednisone TAB
    Dosage: on days 1-5
    Administration route: Oral
    Indication: Waldenstrom's Macroglobulinaemia

Prednisone TAB
    Dosage: on days 1-5
    Administration route: Oral
    Indication: non-Hodgkin's Lymphoma

Prednisone TAB
    Dosage: on days 1-5
    Administration route: Oral

Prednisone TAB
    Dosage: on days 1-5
    Administration route: Oral
    Indication: Lymphoma

Prednisone TAB
    Dosage: on days 1-5
    Administration route: Oral
    Indication: Lymphocytic Lymphoma

Rituximab
    Dosage: on day 1
    Indication: Waldenstrom's Macroglobulinaemia

Rituximab
    Dosage: on day 1

Rituximab
    Dosage: maintenance

Rituximab
    Dosage: on day 1

Rituximab
    Dosage: maintenance
    Indication: Lymphocytic Lymphoma

Rituximab
    Dosage: maintenance
    Indication: B-Cell Lymphoma

Rituximab
    Dosage: on day 1

Rituximab
    Dosage: maintenance
    Indication: non-Hodgkin's Lymphoma

Rituximab
    Dosage: on day 1

Rituximab
    Dosage: maintenance

Rituximab
    Dosage: maintenance
    Indication: Lymphoma

Rituximab
    Dosage: on day 1

Velcade
    Dosage: for every 6 months for 2 years or till progressive disease (maintenance)

Velcade
    Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8
    Indication: B-Cell Lymphoma

Velcade
    Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8

Velcade
    Dosage: for every 6 months for 2 years or till progressive disease (maintenance)

Velcade
    Dosage: for every 6 months for 2 years or till progressive disease (maintenance)

Velcade
    Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8
    Indication: Lymphoma

Velcade
    Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8
    Indication: Waldenstrom's Macroglobulinaemia

Velcade
    Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8

Velcade
    Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8

Velcade
    Dosage: for every 6 months for 2 years or till progressive disease (maintenance)

Velcade
    Dosage: for every 6 months for 2 years or till progressive disease (maintenance)
    Indication: Lymphocytic Lymphoma

Velcade
    Dosage: for every 6 months for 2 years or till progressive disease (maintenance)
    Indication: non-Hodgkin's Lymphoma

Vincristine
    Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3
    Indication: non-Hodgkin's Lymphoma

Vincristine
    Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3

Vincristine
    Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3
    Indication: Waldenstrom's Macroglobulinaemia

Vincristine
    Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3
    Indication: Lymphoma

Vincristine
    Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3
    Indication: B-Cell Lymphoma

Vincristine
    Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3
    Indication: Lymphocytic Lymphoma

Other drugs received by patient: Acetaminophen; Diphenhydramine Hydrochloride; Ondansetron



Possible Cyclophosphamide side effects in female

Reported by a physician from United States on 2012-08-16

Patient: female

Reactions: Abdominal Pain, Vomiting, Nausea, Palmar-Plantar Erythrodysaesthesia Syndrome, Febrile Neutropenia, Peripheral Sensory Neuropathy, Constipation, Fatigue, Diarrhoea, Neutropenia

Drug(s) suspected as cause:
Adriamycin PFS
    Dosage: cycle 3

Adriamycin PFS
    Dosage: cycle 4

Adriamycin PFS
    Dosage: cycle 2

Adriamycin PFS
    Dosage: cycle 1
    Indication: Breast Cancer

Cyclophosphamide
    Dosage: cycle 4

Cyclophosphamide
    Dosage: cycle 3
    Indication: Breast Cancer

Cyclophosphamide
    Dosage: cycle 1

Cyclophosphamide
    Dosage: cycle 2

Docetaxel
    Dosage: cycle 4

Docetaxel
    Dosage: cycle 3
    Indication: Breast Cancer

Docetaxel
    Dosage: cycle 2

Docetaxel
    Dosage: cycle 1

Doxorubicin Hydrochloride
    Dosage: cycle 3

Doxorubicin Hydrochloride
    Dosage: cycle 4
    Indication: Breast Cancer

Doxorubicin Hydrochloride
    Dosage: cycle 1

Doxorubicin Hydrochloride
    Dosage: cycle 2

NOV-002

NOV-002
    Dosage: administered approximately 3 hr apart
    Indication: Breast Cancer

NOV-002



Possible Cyclophosphamide side effects in 65 year old female

Reported by a health professional (non-physician/pharmacist) from Sweden on 2012-08-13

Patient: 65 year old female

Reactions: Myositis, Dysphagia, Nausea, Ataxia, Hemiparesis, Hepatic Enzyme Increased, Dysarthria, Fatigue, Nystagmus, Balance Disorder, Quadriparesis, Vertigo, Arthritis, Progressive Multifocal Leukoencephalopathy

Adverse event resulted in: death

Drug(s) suspected as cause:
Azathioprine Sodium
    Dosage: 150 mg, qd
    Administration route: Oral

Cyclophosphamide
    Dosage: 100 mg, qd
    Administration route: Oral

Methotrexate
    Dosage: 20 mg, qw

Prednisone TAB
    Dosage: 40 mg, qd
    Administration route: Oral

Prednisone TAB
    Dosage: 17.5 mg, qd
    Administration route: Oral

Prednisone TAB
    Dosage: 10 mg, qd
    Administration route: Oral

Prednisone TAB
    Dosage: 40 mg, qd
    Administration route: Oral

Prednisone TAB
    Dosage: 12.5 mg, qd
    Administration route: Oral

Other drugs received by patient: Methylprednisolone; Glucocorticoids; Heparin



Possible Cyclophosphamide side effects in 61 year old female

Reported by a health professional (non-physician/pharmacist) from United States on 2012-08-13

Patient: 61 year old female

Reactions: Mucosal Inflammation, Nausea, Pyrexia, Diffuse Large B-Cell Lymphoma Recurrent, Oral Herpes

Adverse event resulted in: death

Drug(s) suspected as cause:
Bleomycin Sulfate
    Indication: Diffuse Large B-Cell Lymphoma

Cyclophosphamide
    Indication: Diffuse Large B-Cell Lymphoma

Doxorubicin Hydrochloride
    Indication: Diffuse Large B-Cell Lymphoma

Etoposide
    Indication: Diffuse Large B-Cell Lymphoma

Methotrexate
    Indication: Diffuse Large B-Cell Lymphoma

Prednisolone
    Indication: Diffuse Large B-Cell Lymphoma

Vincristine
    Indication: Diffuse Large B-Cell Lymphoma



Possible Cyclophosphamide side effects in

Reported by a physician from United Kingdom on 2012-08-09

Patient:

Reactions: Small Intestinal Obstruction, Vomiting, Nausea, Abdominal Pain Upper

Adverse event resulted in: life threatening event, hospitalization

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: 1340 mg, unk
    Indication: B-Cell Lymphoma
    Start date: 2012-05-11
    End date: 2012-05-30

Doxorubicin Hydrochloride
    Dosage: 90 mg, unk
    Indication: B-Cell Lymphoma
    Start date: 2012-05-11
    End date: 2012-05-30

Prednisolone
    Dosage: 100 mg, unk
    Indication: B-Cell Lymphoma
    Start date: 2012-05-11
    End date: 2012-05-30

Rituximab
    Dosage: 670 mg, unk
    Indication: B-Cell Lymphoma
    Start date: 2012-05-11
    End date: 2012-05-30

Velcade
    Dosage: 2.3 mg, unk
    Indication: B-Cell Lymphoma
    Start date: 2012-05-30
    End date: 2012-06-08

Vincristine
    Dosage: 2 mg, unk
    Indication: B-Cell Lymphoma
    Start date: 2012-05-11
    End date: 2012-05-30

Other drugs received by patient: Acyclovir; Allopurinol; Amitriptyline HCL; Omeprazole; Amitriptyline HCL; Metoclopramide; Metoclopramide



Possible Cyclophosphamide side effects in female

Reported by a physician from Poland on 2012-08-02

Patient: female, weighing 58.0 kg (127.6 pounds)

Reactions: Retroperitoneal Mass, Vomiting, Nausea, Anaemia, Nephropathy Toxic, Folate Deficiency, Iron Deficiency, Herpes Zoster, Vitamin B12 Increased, Asthenia, Beta 2 Microglobulin Increased, Leukopenia

Drug(s) suspected as cause:
Cyclophosphamide
    Indication: Lymphoma
    Start date: 2011-06-22
    End date: 2011-10-27

Doxorubicin Hydrochloride
    Indication: Lymphoma
    Start date: 2011-06-22
    End date: 2011-10-27

Prednisone
    Administration route: Oral
    Indication: Lymphoma
    Start date: 2011-06-22
    End date: 2011-10-27

Rituximab
    Indication: Diffuse Large B-Cell Lymphoma
    Start date: 2011-06-22
    End date: 2011-10-27

Vincristine
    Indication: Lymphoma
    Start date: 2011-06-22
    End date: 2011-10-27

Other drugs received by patient: Heviran; Tamoxifen Citrate



Possible Cyclophosphamide side effects in

Reported by a physician from United States on 2012-08-01

Patient:

Reactions: Nausea, Motor Dysfunction, Pain, Rash, Peripheral Sensory Neuropathy, Fatigue, Dyspepsia, Blood Potassium Decreased, Diarrhoea, Neutropenia, Thrombocytopenia

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: on day 1
    Indication: Waldenstrom's Macroglobulinaemia

Cyclophosphamide
    Dosage: on day 1
    Indication: B-Cell Lymphoma

Cyclophosphamide
    Dosage: on day 1
    Indication: Lymphoma

Cyclophosphamide
    Dosage: on day 1
    Indication: non-Hodgkin's Lymphoma

Cyclophosphamide
    Dosage: on day 1
    Indication: Lymphocytic Lymphoma

Cyclophosphamide
    Dosage: on day 1

Doxorubicin Hydrochloride
    Dosage: on day 1
    Indication: Waldenstrom's Macroglobulinaemia

Doxorubicin Hydrochloride
    Dosage: on day 1
    Indication: Lymphoma

Doxorubicin Hydrochloride
    Dosage: on day 1
    Indication: non-Hodgkin's Lymphoma

Doxorubicin Hydrochloride
    Dosage: on day 1
    Indication: Lymphocytic Lymphoma

Doxorubicin Hydrochloride
    Dosage: on day 1

Doxorubicin Hydrochloride
    Dosage: on day 1
    Indication: B-Cell Lymphoma

Prednisone
    Dosage: on days 1-5
    Administration route: Oral
    Indication: Lymphoma

Prednisone
    Dosage: on days 1-5
    Administration route: Oral
    Indication: B-Cell Lymphoma

Prednisone
    Dosage: on days 1-5
    Administration route: Oral
    Indication: Waldenstrom's Macroglobulinaemia

Prednisone
    Dosage: on days 1-5
    Administration route: Oral
    Indication: Lymphocytic Lymphoma

Prednisone
    Dosage: on days 1-5
    Administration route: Oral

Prednisone
    Dosage: on days 1-5
    Administration route: Oral
    Indication: non-Hodgkin's Lymphoma

Rituximab
    Dosage: maintenance
    Indication: Waldenstrom's Macroglobulinaemia

Rituximab
    Dosage: maintenance

Rituximab
    Dosage: on day 1
    Indication: Lymphocytic Lymphoma

Rituximab
    Dosage: maintenance

Rituximab
    Dosage: on day 1

Rituximab
    Dosage: on day 1
    Indication: B-Cell Lymphoma

Rituximab
    Dosage: on day 1
    Indication: non-Hodgkin's Lymphoma

Rituximab
    Dosage: maintenance

Rituximab
    Dosage: maintenance

Rituximab
    Dosage: on day 1
    Indication: Lymphoma

Rituximab
    Dosage: maintenance

Rituximab
    Dosage: on day 1

Velcade
    Dosage: for every 6 months for 2 years or till progressive disease (maintenance)

Velcade
    Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8

Velcade
    Dosage: for every 6 months for 2 years or till progressive disease (maintenance)
    Indication: non-Hodgkin's Lymphoma

Velcade
    Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8
    Indication: B-Cell Lymphoma

Velcade
    Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8

Velcade
    Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8
    Indication: Lymphoma

Velcade
    Dosage: for every 6 months for 2 years or till progressive disease (maintenance)
    Indication: Lymphocytic Lymphoma

Velcade
    Dosage: for every 6 months for 2 years or till progressive disease (maintenance)

Velcade
    Dosage: for every 6 months for 2 years or till progressive disease (maintenance)

Velcade
    Dosage: for every 6 months for 2 years or till progressive disease (maintenance)

Velcade
    Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8
    Indication: Waldenstrom's Macroglobulinaemia

Velcade
    Dosage: 1.0 to 1.6 mg/m2 on days 1 and 8

Vincristine
    Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3
    Indication: Waldenstrom's Macroglobulinaemia

Vincristine
    Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3
    Indication: Lymphocytic Lymphoma

Vincristine
    Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3

Vincristine
    Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3
    Indication: B-Cell Lymphoma

Vincristine
    Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3
    Indication: non-Hodgkin's Lymphoma

Vincristine
    Dosage: on day 1 not to exceed 1.5 mg from level 1 and 2 and not to exceed 2 mg for level 3
    Indication: Lymphoma

Other drugs received by patient: Diphenhydramine HCL; Acetaminophen; Ondansetron



Possible Cyclophosphamide side effects in

Reported by a physician from United Kingdom on 2012-07-30

Patient:

Reactions: Small Intestinal Obstruction, Vomiting, Nausea, Abdominal Pain Upper

Adverse event resulted in: life threatening event, hospitalization

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: 1340 mg, unk
    Indication: B-Cell Lymphoma
    Start date: 2012-05-11
    End date: 2012-05-30

Doxorubicin Hydrochloride
    Dosage: 90 mg, unk
    Indication: B-Cell Lymphoma
    Start date: 2012-05-11
    End date: 2012-05-30

Prednisolone
    Dosage: 100 mg, unk
    Indication: B-Cell Lymphoma
    Start date: 2012-05-11
    End date: 2012-05-30

Rituximab
    Dosage: 670 mg, unk
    Indication: B-Cell Lymphoma
    Start date: 2012-05-11
    End date: 2012-05-30

Velcade
    Dosage: 2.3 mg, unk
    Indication: B-Cell Lymphoma
    Start date: 2012-05-30
    End date: 2012-06-08

Vincristine
    Dosage: 2 mg, unk
    Indication: B-Cell Lymphoma
    Start date: 2012-05-11
    End date: 2012-05-30

Other drugs received by patient: Omeprazole; Metoclopramide; Amitriptyline Hydrochloride; Allopurinol; Amitriptyline Hydrochloride; Metoclopramide; Acyclovir



Possible Cyclophosphamide side effects in female

Reported by a physician from Germany on 2012-07-27

Patient: female

Reactions: Vomiting, Nausea, Hyponatraemia

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: 1027.5 mg, unk
    Indication: B-Cell Lymphoma
    Start date: 2012-07-04
    End date: 2012-07-04

Doxorubicin Hydrochloride
    Dosage: 66.5 mg, qd
    Indication: B-Cell Lymphoma
    Start date: 2012-07-04
    End date: 2012-07-04

Pegfilgrastim
    Dosage: 6 mg, unk
    Indication: B-Cell Lymphoma
    Start date: 2012-07-08
    End date: 2012-07-08

Prednisone
    Dosage: 100 mg, unk
    Administration route: Oral
    Indication: B-Cell Lymphoma
    Start date: 2012-07-03
    End date: 2012-07-08

Rituximab
    Dosage: 513.75 mg, qd
    Indication: B-Cell Lymphoma
    Start date: 2012-07-04
    End date: 2012-07-04

Vincristine
    Dosage: 2.76 mg, unk
    Indication: B-Cell Lymphoma
    Start date: 2012-07-04
    End date: 2012-07-04

Other drugs received by patient: Allopurinol; Amlodipine Besylate; Losartan Potassium; Pantoprazole Sodium; Metoclopramide; Bisoprolol Fumarate



Possible Cyclophosphamide side effects in female

Reported by a physician from Canada on 2012-07-26

Patient: female

Reactions: Nausea, Palmar-Plantar Erythrodysaesthesia Syndrome, Febrile Neutropenia, Rash, Mucosal Inflammation, Neuropathy Peripheral, Diarrhoea, Alopecia, Ejection Fraction Decreased, Adverse Event, Neutropenia, Cardiotoxicity, Asthenia, Cardiac Failure Congestive

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: 21 day cycle
    Indication: Breast Cancer

Doxorubicin HCL
    Dosage: 21 day cycle
    Indication: Breast Cancer

Taxol
    Dosage: with trastuzumab given weekly for 12 weeks
    Indication: Breast Cancer

Trastuzumab
    Dosage: first dose 4mg/kg given weekly for 12 weeks
    Indication: Breast Cancer

Trastuzumab
    Dosage: first dose 4mg/kg given weekly for 12 weeks



Possible Cyclophosphamide side effects in female

Reported by a physician from Germany on 2012-07-24

Patient: female

Reactions: Vomiting, Nausea

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Allopurinol
    Dosage: 150 mg, qd
    Start date: 2012-06-18

Cyclophosphamide
    Dosage: unk
    Indication: B-Cell Lymphoma
    Start date: 2012-07-04
    End date: 2012-07-04

Doxorubicin HCL
    Dosage: unk
    Indication: B-Cell Lymphoma
    Start date: 2012-07-04
    End date: 2012-07-04

Pegfilgrastim
    Dosage: unk
    Indication: B-Cell Lymphoma
    Start date: 2012-07-08
    End date: 2012-07-08

Prednisone
    Dosage: unk
    Indication: B-Cell Lymphoma
    Start date: 2012-07-04
    End date: 2012-07-04

Rituximab
    Dosage: unk
    Indication: B-Cell Lymphoma
    Start date: 2012-07-07
    End date: 2012-07-07

Vincristine
    Dosage: unk
    Indication: B-Cell Lymphoma
    Start date: 2012-07-04
    End date: 2012-07-04

Other drugs received by patient: Losartan Potassium; Bisoprolol Fumarate



Possible Cyclophosphamide side effects in 48 year old female

Reported by a health professional (non-physician/pharmacist) from Hong Kong on 2012-07-23

Patient: 48 year old female

Reactions: Vomiting, Nausea, Febrile Neutropenia, Oropharyngeal Pain

Adverse event resulted in: life threatening event, hospitalization

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: 830mg, every cycle; 800mg, every cycle
    Indication: non-Small Cell Lung Cancer
    Start date: 2010-10-27

Cyclophosphamide
    Dosage: 830mg, every cycle; 800mg, every cycle
    Indication: non-Small Cell Lung Cancer
    Start date: 2010-10-06
    End date: 2010-10-06

Epirubicin
    Dosage: 166mg every cycle; 140mg, every cycle
    Indication: non-Small Cell Lung Cancer
    Start date: 2010-10-06
    End date: 2010-10-06

Epirubicin
    Dosage: 166mg every cycle; 140mg, every cycle
    Indication: non-Small Cell Lung Cancer
    Start date: 2010-10-27

Fluorouracil
    Dosage: 830 mg every cycle; 700 mg, every cycle
    Indication: Breast Cancer
    Start date: 2010-10-06

Fluorouracil
    Dosage: 830 mg every cycle; 700 mg, every cycle
    Indication: Breast Cancer
    Start date: 2010-10-27



Possible Cyclophosphamide side effects in female

Reported by a physician from Canada on 2012-07-20

Patient: female

Reactions: Nausea, Palmar-Plantar Erythrodysaesthesia Syndrome, Febrile Neutropenia, Rash, Mucosal Inflammation, Neuropathy Peripheral, Diarrhoea, Alopecia, Ejection Fraction Decreased, Adverse Event, Cardiotoxicity, Neutropenia, Asthenia, Cardiac Failure Congestive

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: 21 day cycle
    Indication: Breast Cancer

Doxorubicin HCL
    Dosage: 21 day cycle
    Indication: Breast Cancer

Taxol
    Dosage: with trastuzumab given weekly for 12 weeks
    Indication: Breast Cancer

Trastuzumab
    Dosage: first dose 4mg/kg given weekly for 12 weeks
    Indication: Breast Cancer

Trastuzumab
    Dosage: first dose 4mg/kg given weekly for 12 weeks



Possible Cyclophosphamide side effects in

Reported by a health professional (non-physician/pharmacist) from United States on 2012-07-18

Patient:

Reactions: Pneumonia, Nausea, Lymphopenia, Hyperglycaemia, Anaemia, Febrile Neutropenia, Constipation, Renal Failure, Neuropathy Peripheral, Fatigue, Diarrhoea, Embolism, Neutropenia, Thrombocytopenia, Deep Vein Thrombosis

Adverse event resulted in: death

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: 500 milligram/sq. meter
    Indication: Multiple Myeloma

Dexamethasone
    Dosage: 40 milligram
    Indication: Multiple Myeloma

Revlimid
    Dosage: 25 milligram
    Administration route: Oral
    Indication: Multiple Myeloma

Revlimid
    Dosage: 15 milligram
    Administration route: Oral

Velcade
    Dosage: 1.3 milligram/sq. meter
    Indication: Multiple Myeloma

Velcade
    Dosage: 1.3 milligram/sq. meter



Possible Cyclophosphamide side effects in

Reported by a physician from United Kingdom on 2012-07-17

Patient:

Reactions: Abdominal Pain, Tachycardia, Skin Toxicity, Pyrexia, Fatigue, Neuropathy Peripheral, Hepatotoxicity, Adverse Event, Dizziness, Oedema, Hallucination, Vomiting, Nausea, Gastrointestinal Toxicity, Neutropenic Sepsis, Nephropathy Toxic, Hypotension, Condition Aggravated, Adult T-Cell Lymphoma / Leukaemia, Mucosal Inflammation, Lung Disorder, Infection, Infusion Related Reaction

Adverse event resulted in: death

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: on day 1 of 21 day cycle, (cycle 1-5)
    Indication: Adult T-Cell Lymphoma / Leukaemia

Cytarabine
    Indication: Adult T-Cell Lymphoma / Leukaemia

Doxorubicin HCL
    Dosage: on day 1 of 21 day, (cycle 1-5)

Doxorubicin HCL
    Dosage: on day 1 of 21 day, (cycle 1-5)
    Indication: Adult T-Cell Lymphoma / Leukaemia

Hydrocortisone
    Indication: Adult T-Cell Lymphoma / Leukaemia

Methotrexate
    Indication: Adult T-Cell Lymphoma / Leukaemia

Prednisolone
    Dosage: on days 1-5 of 21 day cycle, (cycle 1-5)
    Administration route: Oral
    Indication: Adult T-Cell Lymphoma / Leukaemia

Radiotherapy
    Indication: Adult T-Cell Lymphoma / Leukaemia

Vincristine
    Dosage: (maximum 2 mg) on day 1 of 21 day cycle, (cycle 1-5)
    Indication: Adult T-Cell Lymphoma / Leukaemia

Zenapax
    Dosage: on days 7 and 14 on cycle 1 of 21 day cycle
    Indication: Adult T-Cell Lymphoma / Leukaemia

Other drugs received by patient: Acyclovir; Thiabendazole; Cotrim; Itraconazole



Possible Cyclophosphamide side effects in female

Reported by a individual with unspecified qualification from United States on 2012-07-16

Patient: female, weighing 50.3 kg (110.7 pounds)

Reactions: Blood Alkaline Phosphatase Increased, Abdominal Pain, Vomiting, Nausea, Epstein-Barr Virus Test Positive, Pyrexia

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: 1275 mg
    End date: 2012-05-16

Fludarabine Phosphate
    Dosage: 126 mg
    End date: 2012-05-16

Rituximab (Moab C2b8 Anti Cd20, Chimeric)
    Dosage: 850 mg
    End date: 2012-05-14



Possible Cyclophosphamide side effects in 62 year old male

Reported by a health professional (non-physician/pharmacist) from United States on 2012-07-13

Patient: 62 year old male, weighing 66.5 kg (146.3 pounds)

Reactions: Vomiting, Nausea

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: 1340 mg once iv
    Indication: Laryngeal Cancer
    Start date: 2012-03-06
    End date: 2012-03-06

Cyclophosphamide
    Dosage: 1340 mg once iv
    Indication: B-Cell Lymphoma
    Start date: 2012-03-06
    End date: 2012-03-06

Vincristine
    Dosage: 2 mg once iv
    Indication: B-Cell Lymphoma
    Start date: 2012-03-06
    End date: 2012-03-06

Vincristine
    Dosage: 2 mg once iv
    Indication: Laryngeal Cancer
    Start date: 2012-03-06
    End date: 2012-03-06



Possible Cyclophosphamide side effects in 28 year old female

Reported by a health professional (non-physician/pharmacist) from United States on 2012-07-11

Patient: 28 year old female

Reactions: Streptococcal Bacteraemia, Vomiting, Nausea, Peripheral Sensorimotor Neuropathy, Carbon Monoxide Diffusing Capacity Decreased, Pancytopenia, Febrile Neutropenia, Hypoaesthesia, Paraesthesia, Gait Disturbance, Coordination Abnormal, Renal Failure Acute

Adverse event resulted in: hospitalization, disablity

Drug(s) suspected as cause:
Bleomycin Sulfate
    Dosage: 15 units/m2 over 24h on day2

Cisplatin
    Dosage: 45 mg/m2, unk

Cisplatin
    Dosage: 90 mg/m2, over 4h on day1
    Indication: Ovarian Cancer

Cyclophosphamide
    Dosage: 750 mg/m2, unk

Cyclophosphamide
    Dosage: 1000 mg/m2, over 60min on day 2
    Indication: Ovarian Cancer

Doxorubicin HCL
    Dosage: 30 mg/m2, unk

Doxorubicin HCL
    Dosage: 45 mg/m2, over 30min on day3
    Indication: Ovarian Cancer

Etoposide
    Dosage: 200 mg/m2, over 2h on day3
    Indication: Ovarian Cancer

Etoposide
    Dosage: 100 mg/m2, unk

Vinblastine
    Dosage: 6 mg/m2, over 30 minutes on day 1
    Indication: Ovarian Cancer

Other drugs received by patient: Pegfilgrastim



Possible Cyclophosphamide side effects in female

Reported by a health professional (non-physician/pharmacist) from Italy on 2012-07-11

Patient: female

Reactions: Vomiting, Nausea, Alopecia, Hypertransaminasaemia

Drug(s) suspected as cause:
Cyclophosphamide
    Indication: Breast Cancer
    Start date: 2011-06-08
    End date: 2011-07-27

Epirubicin Hydrochloride
    Indication: Breast Cancer
    Start date: 2011-06-08
    End date: 2011-07-27

Fluorouracil
    Indication: Breast Cancer
    Start date: 2011-06-08
    End date: 2011-07-27

Other drugs received by patient: Decadron; Kytril; Estrone W / Progesterone; Ramipril



Possible Cyclophosphamide side effects in

Reported by a individual with unspecified qualification from United States on 2012-07-11

Patient:

Reactions: Weight Decreased, Thrombosis, Pruritus, Hypokalaemia, Fatigue, Depression, Thrombocytopenia, Alanine Aminotransferase Abnormal, Blood Antidiuretic Hormone Abnormal, Dyspnoea, Nausea, Lymphopenia, Haemoglobin Abnormal, Hyponatraemia, Febrile Neutropenia, Palmar-Plantar Erythrodysaesthesia Syndrome, Rash, Diarrhoea, Embolism, Blood Alkaline Phosphatase Abnormal, Dehydration, Neutropenia, Leukopenia

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: on days 1-14
    Administration route: Oral
    Indication: Breast Cancer Metastatic

Xeloda
    Dosage: beginning on day 8 and continuing to day 21 (total of 14 days)
    Administration route: Oral
    Indication: Breast Cancer Metastatic



Possible Cyclophosphamide side effects in

Reported by a physician from United Kingdom on 2012-07-10

Patient:

Reactions: Abdominal Pain, Skin Toxicity, Tachycardia, Pyrexia, Fatigue, Neuropathy Peripheral, Hepatotoxicity, Adverse Event, Oedema, Dizziness, Hallucination, Vomiting, Gastrointestinal Toxicity, Nausea, Neutropenic Sepsis, Nephropathy Toxic, Hypotension, Adult T-Cell Lymphoma / Leukaemia, Condition Aggravated, Mucosal Inflammation, Lung Disorder, Infection, Infusion Related Reaction

Adverse event resulted in: death

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: on day 1 of 21 day cycle, (cycle 1-5)
    Indication: Adult T-Cell Lymphoma / Leukaemia

Cytarabine
    Indication: Adult T-Cell Lymphoma / Leukaemia

Doxorubicin HCL
    Dosage: on day 1 of 21 day, (cycle 1-5)
    Indication: Adult T-Cell Lymphoma / Leukaemia

Hydrocortisone
    Indication: Adult T-Cell Lymphoma / Leukaemia

Methotrexate
    Indication: Adult T-Cell Lymphoma / Leukaemia

Prednisolone
    Dosage: on days 1-5 of 21 day cycle, (cycle 1-5)
    Administration route: Oral
    Indication: Adult T-Cell Lymphoma / Leukaemia

Radiotherapy
    Indication: Adult T-Cell Lymphoma / Leukaemia

Vincristine
    Dosage: (maximum 2 mg) on day 1 of 21 day cycle, (cycle 1-5)
    Indication: Adult T-Cell Lymphoma / Leukaemia

Zenapax
    Dosage: on days 7 and 14 on cycle 1 of 21 day cycle
    Indication: Adult T-Cell Lymphoma / Leukaemia

Other drugs received by patient: Cotrim; Itraconazole; Thiabendazole; Acyclovir



Possible Cyclophosphamide side effects in female

Reported by a individual with unspecified qualification from United States on 2012-07-05

Patient: female, weighing 54.0 kg (118.8 pounds)

Reactions: Abdominal Pain, Chills, Pyrexia, Dyspnoea Exertional, Feeling of Body Temperature Change, Decreased Appetite, Cough, Abdominal Pain Lower, Blood Alkaline Phosphatase Increased, Vomiting, Ultrasound Scan Abnormal, Nausea, Alanine Aminotransferase Increased, Haemoglobin Decreased, Poor Personal Hygiene, Aspartate Aminotransferase Increased

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: 1275 mg cyclophosphamide (250mg/m2) over 30 minutes days 1-3 every 28 days.
    End date: 2012-05-16

Fludarabine Phosphate
    Dosage: 126 mg
    End date: 2012-05-16

Rituximab (Moab C2b8 Anti Cd20, Chimeric)
    Dosage: 850 mg
    End date: 2012-05-14



Possible Cyclophosphamide side effects in 28 year old female

Reported by a individual with unspecified qualification from United States on 2012-07-05

Patient: 28 year old female

Reactions: Streptococcal Bacteraemia, Vomiting, Nausea, Pancytopenia, Febrile Neutropenia, Hypoaesthesia, Peripheral Sensory Neuropathy, Paraesthesia, Neuropathy Peripheral, Coordination Abnormal, Gait Disturbance, Peripheral Motor Neuropathy, Renal Failure Acute

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Bleomycin Sulfate
    Dosage: 15 , units/m2, intravenous (not otherwise specified)
    Indication: Ovarian Cancer

Cisplatin
    Dosage: 90 mg/m2, intravenous (not otherwise specified)
    Indication: Ovarian Cancer

Cyclophosphamide
    Dosage: 1000 mg/m2, intravenous (not otherwise specified)
    Indication: Ovarian Cancer

Doxorubicin (Manufacturer Unknown) (Doxorubicin) (Doxorubicin)
    Dosage: 45 mg/m2, intravenous (not otherwise specified)
    Indication: Ovarian Cancer

Etoposide
    Dosage: 200 mg/m2, intravenous (not otherwise specified)
    Indication: Ovarian Cancer

Vinblastine (Manufacturer Unknown) (Vinblastine) (Vinblastine)
    Dosage: 6 mg/m2, intravenous (not otherwise specified)
    Indication: Ovarian Cancer

Other drugs received by patient: Pegfilgrastim (Pegfilgrastim)



Possible Cyclophosphamide side effects in

Reported by a physician from United States on 2012-07-05

Patient:

Reactions: Fatigue, Central Nervous System Haemorrhage, Erythema Multiforme, Dyspnoea, Stomatitis, Vomiting, Gastrointestinal Toxicity, Nausea, Condition Aggravated, Rash, Haematotoxicity, Pulmonary Haemorrhage, Tumour Lysis Syndrome, Diarrhoea, Respiratory Failure, Neurological Symptom, Infection

Adverse event resulted in: death

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: for 5 days in cycle 1
    Indication: Burkitt's Lymphoma

Cyclophosphamide
    Dosage: days 1-5 during cycle 3,5 and 7

Cyclophosphamide
    Dosage: for 5 days in cycle 1
    Indication: Burkitt's Leukaemia

Cyclophosphamide
    Dosage: days 1-5 during cycle 3,5 and 7

Cytarabine
    Dosage: on days 4 and 5 of cycle 2,4 and 6
    Indication: Burkitt's Leukaemia

Cytarabine
    Dosage: on days 4 and 5 of cycle 2,4 and 6
    Indication: Burkitt's Lymphoma

Dexamethasone Sodium Phosphate
    Dosage: on days 1-5 of cycle 2,4 and 6

Dexamethasone Sodium Phosphate
    Dosage: on days 1-5 of cycle 2,4 and 6

Dexamethasone Sodium Phosphate
    Dosage: on days 1-5 of cycle 3,5 and 7
    Indication: Burkitt's Leukaemia

Dexamethasone Sodium Phosphate
    Dosage: on days 1-5 of cycle 3,5 and 7
    Indication: Burkitt's Lymphoma

Doxorubicin HCL
    Dosage: on days 4 and 5 of cycle 3,5 and 7
    Indication: Burkitt's Lymphoma

Doxorubicin HCL
    Dosage: on days 4 and 5 of cycle 3,5 and 7
    Indication: Burkitt's Leukaemia

Etoposide
    Dosage: on days 4 and 5 of cycle 2,4 and 6
    Indication: Burkitt's Lymphoma

Etoposide
    Dosage: on days 4 and 5 of cycle 2,4 and 6
    Indication: Burkitt's Leukaemia

Ifosfamide
    Dosage: on days 1-5 in cycle 2,4 and 6
    Indication: Burkitt's Lymphoma

Ifosfamide
    Dosage: on days 1-5 in cycle 2,4 and 6
    Indication: Burkitt's Leukaemia

Methotrexate
    Dosage: on day 1 of cycle 3,5 and 7
    Indication: Burkitt's Lymphoma

Methotrexate
    Dosage: on day 1 of cycle 2,4 and 6
    Indication: Burkitt's Leukaemia

Methotrexate
    Dosage: on day 1 of cycle 3,5 and 7

Methotrexate
    Dosage: on day 1 of cycle 2,4 and 6

Prednisone
    Dosage: for 7 days in cycle 1
    Indication: Burkitt's Lymphoma

Prednisone
    Dosage: for 7 days in cycle 1
    Indication: Burkitt's Leukaemia

Rituximab
    Dosage: on day 8 from cycle 3 to 7

Rituximab
    Dosage: on day 8 from cycle 3 to 7

Rituximab
    Dosage: day 8 on cycle 2; doage increased to 375 mg/m2 on day 10 and 12
    Indication: Burkitt's Leukaemia

Rituximab
    Dosage: day 8 on cycle 2; doage increased to 375 mg/m2 on day 10 and 12
    Indication: Burkitt's Lymphoma

Vincristine
    Dosage: on day 1 of cycle 3,5 and 7
    Indication: Burkitt's Lymphoma

Vincristine
    Dosage: on day 1 of cycle 2,4 and 6

Vincristine
    Dosage: on day 1 of cycle 3,5 and 7

Vincristine
    Dosage: on day 1 of cycle 2,4 and 6
    Indication: Burkitt's Leukaemia

Other drugs received by patient: Filgrastim; Unknown Medication; Leucovorin Calcium



Possible Cyclophosphamide side effects in

Reported by a physician from United States on 2012-07-05

Patient:

Reactions: Nausea, Anaemia, Chills, Constipation, Fatigue, Neuropathy Peripheral, Alopecia, Adverse Event, Neutropenia, Thrombocytopenia

Drug(s) suspected as cause:
Cyclophosphamide

Cyclophosphamide
    Indication: Chronic Lymphocytic Leukaemia

Cyclophosphamide
    Indication: B-Cell Lymphoma

Doxorubicin HCL
    Dosage: on day 1
    Indication: B-Cell Lymphoma

Doxorubicin HCL
    Dosage: on day 1

Doxorubicin HCL
    Dosage: on day 1
    Indication: Chronic Lymphocytic Leukaemia

Prednisone
    Dosage: on days 1-5
    Administration route: Oral
    Indication: B-Cell Lymphoma

Prednisone
    Dosage: on days 1-5
    Administration route: Oral
    Indication: Chronic Lymphocytic Leukaemia

Prednisone
    Dosage: on days 1-5
    Administration route: Oral

Rituximab
    Dosage: maintenance

Rituximab
    Dosage: on day 1
    Indication: B-Cell Lymphoma

Rituximab
    Dosage: maintenance

Rituximab
    Dosage: on day 1
    Indication: Chronic Lymphocytic Leukaemia

Rituximab
    Dosage: on day 1

Rituximab
    Dosage: maintenance

Velcade
    Dosage: on days 1 and 8

Velcade
    Dosage: on days 1 and 8
    Indication: Chronic Lymphocytic Leukaemia

Velcade
    Dosage: on days 1 and 8
    Indication: B-Cell Lymphoma



Possible Cyclophosphamide side effects in 28 year old female

Reported by a health professional (non-physician/pharmacist) from United States on 2012-06-29

Patient: 28 year old female

Reactions: Streptococcal Bacteraemia, Vomiting, Nausea, Peripheral Sensorimotor Neuropathy, Carbon Monoxide Diffusing Capacity Decreased, Pancytopenia, Febrile Neutropenia, Hypoaesthesia, Paraesthesia, Coordination Abnormal, Gait Disturbance, Renal Failure Acute

Adverse event resulted in: hospitalization, disablity

Drug(s) suspected as cause:
Bleomycin
    Dosage: 15 units/m2 over 24h on day2

Cisplatin
    Dosage: 90 mg/m2 over 4h on day1
    Indication: Ovarian Cancer

Cisplatin
    Dosage: 45 mg/m 2

Cyclophosphamide
    Dosage: 1000 mg/m2 over 60min on day 2
    Indication: Ovarian Cancer

Cyclophosphamide
    Dosage: 750 mg/m 2

Doxorubicin HCL
    Dosage: 45 mg/m2 over 30min on day3
    Indication: Ovarian Cancer

Doxorubicin HCL
    Dosage: 30 mg/m 2

Etoposide
    Dosage: 200 mg/m2 over 2h on day3
    Indication: Ovarian Cancer

Etoposide
    Dosage: 100 mg/m 2

Vinblastine
    Dosage: 6mg/m2 over 30min on day1
    Indication: Ovarian Cancer

Other drugs received by patient: Pegfilgrastim



 Page 1   Next >>

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017